8-K: UFP Technologies Expands Medical Device Portfolio with Acquisition of AJR Enterprises

UFP Technologies has acquired AJR Enterprises, a medical device contract manufacturer specializing in safe patient handling systems, for $110 million.

Summary

• UFP Technologies has completed the acquisition of AJR Enterprises, a medical device contract manufacturer, for $110 million in cash.
• The purchase price is subject to working capital adjustments, and $4 million is held in escrow for indemnification.
• AJR Enterprises specializes in single-use patient safe handling medical devices and had sales of approximately $75 million for the trailing 12 months ended March 31, 2024.
• The acquisition price represents approximately 6.5 times AJR's 2023 adjusted EBITDA.
• UFP Technologies financed the acquisition through an amended and restated credit agreement, increasing its credit facility to $275 million.
• The new credit facility includes a $125 million term loan and a $150 million revolving credit facility, maturing on June 27, 2029.
• As of July 1, 2024, UFP had $150 million in borrowings outstanding under the new credit facilities.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the strategic benefits of the acquisition and the company's growth prospects. However, the increased debt and integration risks temper the overall sentiment.

Positives

• The acquisition expands UFP Technologies' capabilities in the growing market of patient surfaces and transfer devices.
• AJR's expertise in cut and sew manufacturing and specialty fabrics aligns well with UFP's strategy.
• The combined companies will offer comprehensive design and manufacturing services in the safe patient handling space.
• The acquisition is expected to bring more value to UFP's customers through expanded capabilities and locations.

Negatives

• The acquisition was financed with a significant increase in debt, which could increase financial risk.
• The purchase price is subject to working capital adjustments, which could impact the final cost.

Risks

• The integration of AJR Enterprises may present challenges and may not yield the anticipated benefits.
• The company is exposed to risks and uncertainties that could affect its business and prospects.
• The company is exposed to risks and uncertainties that could affect its business and prospects, including the ability to execute its business strategy and integration strategy.

Future Outlook

The press release contains forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. The company disclaims any obligation to update these statements.

Management Comments

• We are very excited to add AJR Enterprises capabilities to our patient surfaces portfolio, said R. Jeffrey Bailly, chairman and CEO of UFP Technologies.
• Combined with our thermoplastic joining expertise, we can now offer a comprehensive suite of development, commercialization, and manufacturing services for this market, said Bailly.
• With UFP Technologies ability to expand our capabilities and continue our high standards in quality and service, we found the perfect fit, said John Rukel, chief operating officer, AJR Group.
• Together, our companies will offer extraordinary design and manufacturing capabilities across the safe patient handling space. We are confident that UFP will continue to grow the business while maintaining the culture and values we have built over the past 25 years.

Industry Context

The acquisition reflects a trend in the medical device industry towards consolidation and expansion of capabilities in high-growth areas like safe patient handling. The acquisition allows UFP Technologies to strengthen its position in the medical device supply chain and offer a more comprehensive suite of services.

Comparison to Industry Standards

• The acquisition multiple of 6.5x adjusted EBITDA is within the typical range for acquisitions in the medical device contract manufacturing sector.
• Comparable companies in the medical device contract manufacturing space often trade at similar or higher multiples depending on growth prospects and profitability.
• The increase in UFP Technologies' credit facility to $275 million is a significant move, reflecting the scale of the acquisition and the company's growth ambitions.
• The terms of the credit facility, including the maturity date of June 27, 2029, are consistent with typical financing arrangements for acquisitions of this size.

Stakeholder Impact

• Shareholders may benefit from the expanded market presence and growth potential of the combined company.
• Employees of both UFP Technologies and AJR Enterprises may experience changes due to the integration process.
• Customers of both companies will have access to a broader range of products and services.
• Suppliers may see increased business opportunities as the combined company grows.
• Creditors will be impacted by the increased debt levels of UFP Technologies.

Next Steps

• UFP Technologies will integrate AJR Enterprises into its existing operations.
• The company will focus on leveraging the combined capabilities to offer comprehensive solutions in the safe patient handling market.
• UFP Technologies will continue to monitor and manage the financial impact of the acquisition and the new credit facility.

Key Dates

Keywords

acquisition, medical devices, patient handling, contract manufacturing, credit facility, EBITDA, safe patient handling, term loan, revolving credit, UFP Technologies, AJR Enterprises